Early onset of diffuse melanosis cutis under pembrolizumab therapy illustrates the limitations of anti-PD-1 checkpoint inhibitors-Reference-Cited by-同舟云学术

Early onset of diffuse melanosis cutis under pembrolizumab therapy illustrates the limitations of anti-PD-1 checkpoint inhibitors

Published:2018-10 Issue:5 Volume:28 Page:465-468
ISSN:0960-8931
Container-title:Melanoma Research
language:en
Short-container-title:

Author:

Thiem Alexander,Schummer Patrick,Ueberschaar Simon,Kerstan Andreas,Kneitz Hermann,Schrama David,Appenzeller Silke,Meierjohann Svenja,Schilling Bastian,Goebeler Matthias,Gesierich Anja

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Dermatology,Oncology

Reference14 articles.

1. Pathogenesis of generalized dermal pigmentation secondary to malignant melanoma and melanuria;Fitzpatrick;J Invest Dermatol,1954

2. Diffuse melanosis cutis: a systematic review of the literature;Sebaratnam;J Am Acad Dermatol,2013

3. Pembrolizumab versus ipilimumab in advanced melanoma;Robert;N Engl J Med,2015

4. Coincident metastatic melanoma and merkel cell carcinoma with complete remission on treatment with pembrolizumab;Thiem;Acta Derm Venereol,2017

5. Diffuse melanosis after chemotherapy-induced tumor lysis syndrome in a patient with metastatic melanoma;Busam;J Cutan Pathol,2004

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diffuse Melanosis Cutis as the First Sign of Recurrence of Low-Risk Melanoma: Case Report and Systematic Review;Dermatology Practical & Conceptual;2024-01-31

2. Melanuria in a patient with BRAF-mutant metastatic melanoma of unknown primary: Insights on the pathophysiology, differential diagnosis, prognosis, and treatment;The American Journal of the Medical Sciences;2023-04

3. Blue Facial Discoloration during Advanced Cancer and a Pandemic;Journal of Pain and Symptom Management;2021-09

4. Cutaneous Events Associated with Immunotherapy of Melanoma: A Review;Journal of Clinical Medicine;2021-07-08

5. Diffuse Hyperpigmentation in a Patient With an Axillary Mass;JAMA Oncology;2019-08-01